# Immunochemical Characterization of Anti-Acetylcholinesterase Inhibitory Monoclonal Antibodies

**Title and Subtitle**

Immunochemical Characterization of Anti-Acetylcholinesterase Inhibitory Monoclonal Antibodies

**Authors**

Mary K. Gentry, Ashima Saxena, Yacov Ashani, and B. P. Doctor

**Performing Organization**

Division of Biochemistry
Walter Reed Army Institute of Research
Washington, DC 20307-5100

**Sponsoring Agency**

U. S. Army Medical Research & Development Command
Fort Detrick, Frederick, MD 21701
Walter Reed Army Institute of Research
Washington, DC 20307-5100

**Abstract**

Monoclonal antibodies (mAbs) were prepared against native of DFP-inhibited *Torpedo californica* acetylcholinesterase and native or DFP-, MEPQ-, and soman-inhibited fetal bovine serum acetylcholinesterase. The cross reactivity of these antibodies with acetylcholinesterases from various species and their ability to inhibit catalytic activity were determined. Eight antibodies were found to inhibit catalytic activity of either *Torpedo* or fetal bovine serum enzyme. In all cases the antibodies bound to the native form of the enzymes and in some cases even to the denatured form. None of the antibodies recognized human or horse serum butyrylcholinesterase. Sucrose density gradient centrifugation of enzyme-antibody complexes provided two types of profiles, one with multiple peaks, indicating numerous complexes between tetrameric forms of the enzyme, and the other with single peaks, demonstrating complex formation within the tetrameric form. Different antibodies appeared to interact with slightly different regions, but in all cases the binding encompassed the peripheral anionic site. Decrease in catalytic activity of the enzyme was most likely caused by conformational changes in the enzyme molecule resulting from interaction with these mAbs.

**Subject Terms**

Monoclonal antibodies, anti-cholinesterase, inhibition, fetal bovine serum acetylcholinesterase, *Torpedo californica* acetylcholinesterase

**Distribution/Availability Statement**

Approved for public release: distribution unlimited.
Best Available Copy
The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to stay within the lines to meet optical scanning requirements.

**Block 1. Agency Use Only (Leave Blank)**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<table>
<thead>
<tr>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>Contract</td>
</tr>
<tr>
<td>G</td>
<td>Grant</td>
</tr>
<tr>
<td>PE</td>
<td>Program</td>
</tr>
<tr>
<td>TA</td>
<td>Task</td>
</tr>
<tr>
<td>WU</td>
<td>Work Unit</td>
</tr>
<tr>
<td>Element Accession No.</td>
<td></td>
</tr>
</tbody>
</table>

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Names(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of .... To be published in .... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denote public availability or limitation. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR)

<table>
<thead>
<tr>
<th>Agency</th>
<th>Distribution/Availability Statement</th>
</tr>
</thead>
</table>
| DOD    | See DoDD 5230.24, "Distribution Statements on Technical Documents."
| DOE    | See authorities                     |
| NASA   | See Handbook NHB 2200.2.            |
| NTIS   | Leave blank                         |

**Block 12b. Distribution Code.**

<table>
<thead>
<tr>
<th>Agency</th>
<th>Distribution Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOD</td>
<td>DOD - Leave blank</td>
</tr>
<tr>
<td>DOE</td>
<td>DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports</td>
</tr>
<tr>
<td>NASA</td>
<td>NASA - Leave blank</td>
</tr>
<tr>
<td>NTIS</td>
<td>NTIS - Leave blank</td>
</tr>
</tbody>
</table>

**Block 13. Abstract.** Include a brief (Maximum 200 words) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (NTIS only).


**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.
IMMUNOCHEMICAL CHARACTERIZATION OF ANTI-ACETYLCHOLINESTERASE INHIBITORY MONOCLONAL ANTIBODIES

MARY K. GENTRY*, ASHIMA SAXENA*, YACOV ASHANI† and BHUPENDRA P. DOCTOR*

*Division of Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307-5100 (USA) and †Israel Institute for Biological Research, Ness-Ziona (Israel)

SUMMARY

Monoclonal antibodies (mAbs) were prepared against native or DFP-inhibited Torpedo californica acetylcholinesterase and native or DFP-, MEPQ-, and soman-inhibited fetal bovine serum acetylcholinesterase. The cross reactivity of these antibodies with acetylcholinesterases from various species and their ability to inhibit catalytic activity were determined. Eight antibodies were found to inhibit catalytic activity of either Torpedo or fetal bovine serum enzyme. In all cases the antibodies bound to the native form of the enzymes and in some cases even to the denatured form. None of the antibodies recognized human or horse serum butyrylcholinesterase. Sucrose density gradient centrifugation of enzyme-antibody complexes provided two types of profiles, one with multiple peaks, indicating numerous complexes between tetrameric forms of the enzyme, and the other with single peaks, demonstrating complex formation within the tetrameric form. Different antibodies appeared to interact with slightly different regions, but in all cases the binding encompassed the peripheral anionic site. Decrease in catalytic activity of the enzyme was most likely caused by conformational changes in the enzyme molecule resulting from interaction with these mAbs.

Key words: Monoclonal antibodies – Anti-cholinesterase – Inhibition – Fetal bovine serum acetylcholinesterase – Torpedo californica acetylcholinesterase

INTRODUCTION

Monoclonal antibodies (mAbs) have been employed as molecular probes to map and investigate the surface topology of cholinesterases (ChEs) and other similar enzymes [1–4]. Those monoclonal antibodies that, upon interaction with...
enzymes, affect catalytic function by inhibition, stimulation, or other means, are of special interest. Elucidation of the structure-function correlation of ChEs can be facilitated by studying the nature of interaction of such mAbs with ChEs, since they are presumed to be directed against an epitope that either constitutes or affects the catalytic machinery of the enzyme. It can be assumed that this epitope is not the active center, since this site is located in a pocket-like conformation. This conformation was first proposed using studies with monoclonal antibodies against a synthetic peptide mimicking the sequence of the active site of fetal bovine serum acetylcholinesterase [2] and confirmed by X-ray crystallography of the enzyme from *Torpedo californica* [5]. We describe here the modulation of catalytic activity of acetylcholinesterase following the interaction with inhibitory mAbs raised against fetal bovine serum acetylcholinesterase (FBS AChE) and *T. californica* AChE. Our results indicate that although these mAbs appear to bind to a conformational epitope located in a region remote from the catalytic site that is at or near the peripheral site, the conformational changes caused in the molecule modulate the catalytic mechanism.

**MATERIALS AND METHODS**

Mice were immunized with a mixture of 5.6 S hydrophobic dimer and asymmetric (17+13) S forms of *T. californica* AChE, native FBS AChE, DFP-inhibited FBS AChE, soman-inhibited FBS AChE, or MEPQ-inhibited FBS AChE. Details of the fusions have been previously published [1,3,6]. Enzymes from fetal bovine, fetal equine, human sheep, pig, rabbit, goat, and horse sera were isolated using the method of De La Hoz et al. [7] using sera from commercial sources. Inhibition of serum enzymes was assessed by a microplate adaptation of the Ellman assay [8]. Recognition of serum enzymes by antibodies was measured by ELISA, using purified enzymes to coat the plates and a horseradish peroxidase-conjugated anti-mouse antibody to detect binding. Sucrose density gradients were used to estimate the size and the nature of complexes formed between monoclonal antibodies and FBS AChE. Edrophonium, an esteratic-site ligand, and propidium, a peripheral anionic-site ligand, were employed to determine whether binding of antibodies interfered with the hydrolysis of acetylthiocholine by AChE. Prevention or reduction of DFP binding and displacement of DFP by TMB₄ in enzyme/antibody complexes were also assessed.

**RESULTS AND DISCUSSION**

A total of eight inhibitory monoclonal antibodies were produced, two (2C8, 7G4) from mice immunized with *Torpedo* AChE, one each from fusions with native (13D8) and DFP-inhibited FBS AChE (25B1), and four (2A1, 4E5, 5E8, and 6H9) from a fusion with MEPQ-FBS AChE as the immunogen (Table I). No inhibitory antibodies resulted from a soman-FBS AChE immunization, although immunization and fusion were done under identical conditions as the MEPQ-AChE fusion.

None of the antibodies showed any cross-reactivity in inhibition patterns, i.e.,
TABLE I
IMMUNOCHEMICAL CHARACTERIZATION OF ANTI-ACETYLCOLINESTERASE MONOCLONAL ANTIBODIES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>13D8, IgG$_1$</td>
<td>FBS AChE</td>
<td>84</td>
<td>14</td>
<td>0</td>
<td>$\geq 860,000$</td>
<td>0/0</td>
</tr>
<tr>
<td>25B1, IgG$_1$</td>
<td>DFP-FBS AChE</td>
<td>$&gt;98$</td>
<td>7</td>
<td>5</td>
<td>$860,000$</td>
<td>0/+</td>
</tr>
<tr>
<td>2A1, IgG$_1$</td>
<td>MEPQ-FBS AChE</td>
<td>92</td>
<td>26</td>
<td>67</td>
<td>$860,000$</td>
<td>0/+</td>
</tr>
<tr>
<td>4E5, IgG$_1$</td>
<td>MEPQ-FBS AChE</td>
<td>$&gt;98$</td>
<td>10</td>
<td>59</td>
<td>$580,000$</td>
<td>0/+</td>
</tr>
<tr>
<td>5E8, IgG$_2$</td>
<td>MEPQ-FBS AChE</td>
<td>$&gt;98$</td>
<td>17</td>
<td>49</td>
<td>$430,000$</td>
<td>0/+</td>
</tr>
<tr>
<td>6H9, IgG$_2$</td>
<td>MEPQ-FBS AChE</td>
<td>$&gt;98$</td>
<td>5</td>
<td>75</td>
<td>$430,000$</td>
<td>0/+</td>
</tr>
<tr>
<td>None</td>
<td>FBS AChE</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td></td>
<td>N.D.</td>
</tr>
<tr>
<td>2C8, IgG$_1$</td>
<td>Torpedo AChE</td>
<td>93</td>
<td>83</td>
<td>80</td>
<td>$860,000$</td>
<td>N.D.</td>
</tr>
<tr>
<td>7G4, IgG$_1$</td>
<td>Torpedo AChE</td>
<td>95</td>
<td>48</td>
<td>85</td>
<td>$860,000$</td>
<td>N.D.</td>
</tr>
<tr>
<td>None</td>
<td>Torpedo AChE</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Equal amounts of either FBS AChE or Torpedo californica 11S AChE and appropriate amounts of monoclonal antibody were incubated at room temperature for 24 h and assayed for residual enzyme activity.

*Enzyme:antibody complexes formed after 24 h incubation (see above) were incubated for an additional 24 h with a 2-fold molar excess (to enzyme) of $[^3]$HDFP. Enzyme:mAb:$[^3]$HDFP was separated from free $[^3]$HDFP by Bio-Rad P-6 gel filtration chromatography. Radioactivity eluting with enzyme alone was used as the 100% control to compare with labeling of various enzyme:mAb complexes.

*FBS AChE and Torpedo AChE were prelabeled with $[^3]$HDFP (2-fold molar excess) by incubating at room temperature for 24 h. Enzyme:$[^3]$HDFP complex was isolated by gel filtration on Bio-Rad P-6 columns and incubated with mAb for 24 h, followed by incubation for 48 h with 1 mM TMB$_4$. Separation by P-6 column chromatography allowed determination of the amount of radioactivity bound to enzyme or enzyme:mAb.

*Estimated mw carbon of AChE:mAb complexes formed, as determined by sucrose density gradient centrifugation (5-20%) using molecular weights of 280,000 for FBS AChE (tetrameric form) and 150,000 for antibody.

*The relative effect of edrophonium (upper symbol) and propidium (lower symbol) on the rate of acetylthiocholine hydrolysis; zero, no effect; +, change in rate of inhibition by mAb.
anti-FBS AChE antibodies did not inhibit Torpedo enzyme and vice versa. Four mAbs (25B1, 4E5, 5E8, and 6H9) inhibited FBS AChE greater than 98% at an enzyme:mAb ratio of 1:1 – 1:5. Antibodies 13D8 and 2A1 partially inhibited FBS AChE, 84% and 92%, respectively; antibodies 2C8 and 7G4 partially inhibited Torpedo AChE, 93% and 95%, respectively.

None of the antibodies recognized or inhibited butyrylcholinesterase from either human or horse serum. As determined by ELISA, all anti-FBS AChE antibodies recognized the cholinesterase from the serum of sheep, rabbits, and goats, that was identified as acetylcholinesterase by use of the specific inhibitors BW284C51 and iso-OMPA [9]. None of these antibodies recognized enzyme isolated from pig, horse, fetal equine, or human sera, identified as butyrylcholinesterase by the same inhibitors. All anti-FBS AChE antibodies recognized epitopes on recombinant human AChE, although the binding was minimal. Five of the six anti-FBS AChE antibodies were able to bind to some extent to reduced, denatured, and alkylated FBS AChE.

Sucrose density gradient centrifugation of (tetrameric) enzyme-antibody complexes revealed that some anti-FBS AChE mAbs (4E5, 5E8, 6H9) produced complexes of a discrete size, while others (25B1, 13D8, 2A1) formed multimeric complexes. The distance between epitopes or their orientation on the surface of catalytic subunits of the tetrameric form of FBS AChE for the first group of antibodies appears to be such that the complex is composed of only a single tetramer and either one or two antibody molecules. For mAbs 5E8 and 6H9, the orientation of the first bound antibody molecule appears to prevent the binding of a second antibody molecule, while in the case of mAb 4E5, the epitopes seem to be oriented so that each tetramer can bind two antibody molecules. For the second group of mAbs, those forming multimeric complexes, the distance between their epitopes must be different or the location must be such that the antibodies can bridge between tetramers, since the complexes appear to be formed of more than one tetramer and more than two antibody molecules.

Inhibition reactions measuring decrease in FBS AChE activity following complexation with the six anti-FBS AChE mAbs were somewhat different for each antibody. However, propidium was found to be somewhat more effective than edrophonium in inhibiting the complexation reaction, suggesting that these antibodies bind in the vicinity of the peripheral anionic site of the enzyme.

Five of six anti-FBS AChE mAbs effectively interfered with the binding of $[^3H]DFP$ to FBS AChE after enzyme:antibody complexes were formed. When FBS enzyme was inhibited by anti-FBS AChE monoclonal antibodies, the binding of $[^3H]DFP$ to enzyme was markedly retarded (only 5 – 17% bound after 24 h). Antibody 2A1 was less efficient at retarding DFP binding, allowing 26% to be bound, even though enzyme inhibition was 92%. The anti-Torpedo AChE antibodies only partially prevented $[^3H]DFP$ binding to the Torpedo enzyme. For complexes of two mAbs, 13D8 and 25B1, with FBS AChE and $[^3H]DFP$, TMB$_4$ was effective at dissociating $[^3H]DFP$. For the remaining antibodies and their complexes, TMB$_4$ only partially dissociated the DFP (49 – 85%). These results suggest that binding of all anti-FBS AChE mAbs to a region of the enzyme which is remote to the catalytic site affects acylation/phosphorylation. The dissociation
of DFP by TMB₄ from the complex with mAbs 25B1 and 13D8 suggests that in these two cases the deacylation/phosphorylation mechanism of the enzyme is still functioning, which is not true with the other mAbs.

The results presented here indicate that the change in conformation of AChE caused by the complex formation between anti-AChE mAbs and the enzyme in a region remote to the active site affects the catalytic mechanism of the enzyme.

ACKNOWLEDGMENTS

This work could not have been completed without the expert technical assistance of Regina S. Hur and Deborah R. Moorad.

REFERENCES